

DAFTAR PUSTAKA

- Angelico, G., Broggi, G., Caltabiano, R., Santoro, A., Spadola, S., D'Alessandris, N., Scaglione, G., Valente, M., Arciuolo, D., Sanchez, A. M., Franceschini, G., Masetti, R., Mulè, A., Zannoni, G. F. 2021. Histopathological Evaluation of Tumor-Infiltrating Lymphocytes (TILs) as Predictive Biomarker for Hormone Receptor Status, Proliferative Activity and Clinical Outcome in Her2-Positive Breast Cancer. *Applied Sciences*, 11(15), 6788.
- Arianto, B., Hendarsih, E., Nursa'adah, A., Purnami, N. 2024. Characteristics of Breast Cancer at General Hospital Haji Surabaya. *International Journal of Multidisciplinary and Current Educational Research*, 6(3): 881-885.
- Bahreyni, A., Mohamud, Y., Luo, H. 2024. Oncolytic virus-based combination therapy in breast cancer. *Cancer Letters*, 585, 216634.
- Bates, J. P., Derakhshandeh, R., Jones, L., Webb, T. J. 2018. Mechanisms of Immune Evasion in Breast Cancer. *BMC*, 18: 556.
- Bhaskaran, K., Douglas, I., Forbes, H., dos-Santos-Silva, I., Leon, D.A. and Smeeth, L. 2014. Body-mass index and risk of 22 specific cancers: a population-based cohort study of 5.24 million UK adults. *The Lancet*, 384(9945), pp. 755–765.
- Bray, F., Laversanne, M., Sung, H., Ferlay, J., Siegel, R. L., Soerjomataram, I., Jemal, A. 2024. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin*, 74(3): 229-263.
- Cheng, X. 2024. A Comprehensive Review of HER2 in Cancer Biology and Therapeutics. In *Genes*, 15(7): 903. *Multidisciplinary Digital Publishing Institute* (MDPI). <https://doi.org/10.3390/genes15070903>
- Ciarka, A., Piatek, M., Peksa, R., Kunc, M., Senkus, E. 2024. Tumor-Infiltrating Lymphocytes (TILs) in Breast Cancer: Prognostic and Predictive Significance across Molecular Subtypes. *Biomedicines*, 12(4), 763.
- Deanasa, R. S., Umar, M., Fitri, A. D. 2022. Overall Survival for Stage III Breast Cancer Patients at DR. Mohammad Hoesin General Hospital Palembang and the Influencing Factors. *Indonesian Journal of Cancer*, 16(4): 231-237.
- Denkert, C., von Minckwitz, G., Brase, J. C., Sinn, B. V., Gade, S., Kronenwett, R., Pfitzner, B. M., Salat, C., Loi, S., Schmitt, W. D., Schem, C., Fisch, K., Darb-Esfahani, S., Mehta, K., Sotiriou, C., Wienert, S., Klare, P., André, F., Klauschen, F., Blohmer, J. U., Loibl, S. 2015. Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-

- negative primary breast cancers. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*, 33(9), 983–991.
- Desmedt, C., Salgado, R., Fornili, M., Pruneri, G., Eynden, G. V., Zoppoli, G., Rothé, F., Buisseret, L., Garaud, S., Bertucci, F., Loi, S., Viale, G., Di Leo, A., Green, A. R., Ellis, I. O., Rakha, E. A., Larsimont, D., Biganzoli, E., Sotiriou, C. 2018. Immune Infiltration in Invasive Lobular Breast Cancer. *Journal of the National Cancer Institute*, 110(7): 768–776.
- Dewi, G. A. T., Hendrati, L. Y. 2015. Analisis Risiko *Carcinoma* Payudara Berdasar Riwayat Pemakaian Kontrasepsi Hormonal dan Usia *Menarche*. *Jurnal Berbasis Epidemiologi*, 3(1): 12-23.
- Diana, D., Kusmardi. 2020. Tumor-*infiltrating lymphocytes* dan Peranannya pada *Carcinoma* Payudara. *Majalah Patologi Indonesia*, 29(1): 30-40.
- Dieci, M. V., Mathieu, M. C., Guarneri, V., Conte, P., Delaloge, S., Andre, F., & Goubar, A. 2015. Prognostic and predictive value of tumor-infiltrating lymphocytes in two phase III randomized adjuvant breast cancer trials. *Annals of oncology : official journal of the European Society for Medical Oncology*, 26(8), 1698–1704.
- Efni, N., Fatmawati, T. Y. 2021. Edukasi Deteksi Dini *Carcinoma* Payudara melalui Pemeriksaan Payudara Sendiri (SADARI) di SMA N 8 Kota Jambi. *Jurnal Abdimas Kesehatan*, 3(1): 28-32.
- Ferlay, J., Ervik, M., Lam, F., Laversanne, M., Colombier, M., Mery, L., Piñeros, M., Znaor, A., Soerjomataram, I., Bray, F. 2024. Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: <https://gco.iarc.who.int/today>, accessed [25 Agustus 2024].
- Fitzpatrick, D., Pirie, K., Reeves, G., Green, J. and Beral, V. 2023. Combined and progestagen-only hormonal contraceptives and breast cancer risk: A UK nested case-control study and meta-analysis. *PLOS Medicine*, 20(3), e1004188.
- Fudalej, M., Sobiborowicz-Sadowska, A., Mormul, A., Jopek, S., Borowlec, A., Sikorsi, P., Patera, J., Deptala, A., Badowska-Kozakiewicz, A. M. 2024. The Comparison Between The Two Most Common Histological Subtypes of Breast Cancer - Invasive Ductal and Invasive Lobular Breast Carcinoma. *OncoReview*, 14 (1(53): 9-15.
- Gaudet, M.M., Gapstur, S.M., Sun, J., Diver, W.R., Hannan, L.M. and Thun, M.J. 2013. Active smoking and breast cancer risk: Original cohort data and meta-analysis. *Journal of the National Cancer Institute*, 105(8), 515–525.
- Gondhowiardjo, S., Soediro, R., Jayalie, V. F., Djoerban, Z., Siregar, N. C., Poetiray, E. D. C. 2020. Multicenter management of breast cancer in

- indonesia: ten years of experience. *Multicenter Management of Breast Cancer in Indonesia*, 8(2): 121-130.
- Hall, J. E., Hall, M. E. 2021. *Guyton and Hall Textbook of Medical Physiology* 14th Edition. Philadelphia, Elsevier.
- Hortobagyi, G.N., Connolly, J.L., D'Orsi, C.J., Edge, S.B., Mittendorf, E.A., Rugo, H.S., Solin, L.J., Weaver, D.L., Winchester, D.J. and Giuliano, A., 2017. Breast. In: M.B. Amin et al., eds. *AJCC Cancer Staging Manual*. 8th ed. Chicago, IL: American College of Surgeons, pp.589–622.
- Irawan, M. F., Syahril, E., Chalid, A., Gunawan, M. I., Christina, L. P. 2025. Evaluasi kejadian *carcinoma* payudara di RS ibnu sina kota makassar tahun 2024. *Fakumi Medical Journal*, 5(1): 14-21.
- Kemenkes. 2018. *Pedoman Nasional Pelayanan Kedokteran Tata Laksana Carcinoma Payudara*. Kementerian Kesehatan RI, Jakarta.
- Kemenkes. 2015. *Panduan Nasional Penanganan Carcinoma Payudara*. Kementerian Kesehatan RI, Jakarta.
- Kementerian Kesehatan Republik Indonesia . 2022. *Profil Kesehatan Indonesia Tahun 2022*. Jakarta: Kementerian Kesehatan RI.
- Kurozumi, S., Inoue, K., Matsumoto, H., Fujii, T., Horiguchi, J., Oyama, T., Kurosumi, M., Shirabe, K. 2019. Clinicopathological Values of PD-L1 Expression in HER2-positive Breast Cancer. *Scientific Reports*, 9: 16662.
- Kumar, V., Abbas, A. K., Aster, J. C. 2018. *Robbins Basic Pathology* 10th Edition. Philadelphia, Elsevier.
- Lauby-Secretan, B., Scoccianti, C., Loomis, D., Grosse, Y., Bianchini, F. and Straif, K. 2016. Body fatness and cancer — viewpoint of the IARC Working Group. *The New England Journal of Medicine*, 375(8), 794–798.
- Lawrenti, H. 2023. Terapi *Carcinoma* Payudara Stadium Lanjut HER2 (+). *Cermin Dunia Kedokteran*, 50(10): 565-569.
- Loi, S., Michiels, S., Salgado, R., Sirtaine, N., Jose, V., Fumagalli, D., Kellokumpu-Lehtinen, P. L., Bono, P., Kataja, V., Desmedt, C., Piccart, M. J., Loibl, S., Denkert, C., Smyth, M. J., Joensuu, H., & Sotiriou, C. 2014. Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. *Annals of oncology : official journal of the European Society for Medical Oncology*, 25(8), 1544–1550.
- Lu, Y., Tong, Y., Fei, X., Chen, X., & Shen, K. 2023. Clinical characteristics, tumor-infiltrating lymphocytes, and prognosis in HER2-low breast cancer: A comparison study with HER2-zero and HER2-positive disease. *Cancer medicine*, 12(15), 16264–16278.

- Łukasiewicz, S., Czezelewski, M., Forma, A., Baj, J., Sitarz, R., & Stanisławek, A. (2021). Breast Cancer—Epidemiology, Risk Factors, Classification, Prognostic Markers, and Current Treatment Strategies—An Updated Review. *Cancers*, 13(17), 4287.
- Lv, Q., Meng, Z., Yu, Y., Jiang, F., Guan, D., Liang, C., Zhou, J., Lu, A., & Zhang, G. 2016. Molecular mechanisms and translational therapies for human epidermal receptor 2 positive breast cancer. In *International Journal of Molecular Sciences*, 17(12): 2025. MDPI AG.
- Mariani, N., Margiana, W. 2023. Gambaran karakteristik tingkat pengetahuan *carcinoma* payudara remaja putri di SMK Bakti Purwokerto. *Proceedings Series on Health & Medical Sciences*, 4: 37-40.
- Melinda, R., Siwi, A. S., Wirakhmi, I. N. 2024. Overview of Sexuality Satisfaction in Breast Cance Patients at RSUD Prof. Dr. Margono Soekarjo Purwokerto. *Jurnal Kesehatan, Kebidanan, dan Keperawatan*, 17(02): 265-273.
- Menon, G., Alkabban, FM., Ferguson, T. 2024. *Breast Cancer*. Treasure Island (FL): StatPearls Publishing. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK482286/>, accessed [26 April 2025].
- Nascimento, R. G. do, & Otoni, K. M. 2020. Histological and molecular classification of breast cancer: what do we know? *Mastology*, 30.
- Olfatbakhsh, A., Heidari, A., Omidi, Z., Hashemi, E. S., Ansari, M., Mozaffarian, S., Haghighat, S. 2022. Long-term Survival and Prognostic Factors of Breast Cancer. *Archives of Iranian Medicine*, 25(9): 609-616.
- Orrantia-Borunda, E., Anchondo-Nuñez, P., Acuña-Aguilar, L.E., Gómez-Valles, F. O., Ramirez-Valdespino, C. A. 2020. Subtypes of breast cancer. In: Mayrovitz HN. editor. *Breast Cancer*. Brisbane (AU): Exon Publications. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK583808/>, accessed [27 Agustus 2024].
- Ortiz-Godoy, A., Sanchez-Muñoz, A., Parrado, M. R. C., Álvarez, M., Ribelles, N., Dominguez A. R., Alba, E. 2019. Deciphering HER2 breast cancer disease: biological and clinical implications. *Frontiers in oncology*, 9(1124).
- Picon-Ruiz, M., Morata-Tarifa, C., Valle-Goffin, J.J., Friedman, E.R. and Slingerland, J.M. 2017. Obesity and adverse breast cancer risk and outcome: Mechanistic insights and strategies for intervention. *CA: A Cancer Journal for Clinicians*, 67(5), 378–397.
- Pruneri, G., Vingiani, A., Bagnardi, V., Rotmensz, N., De Rose, A., Palazzo, A., Colleoni, A. M., Goldhirsch, A., Viale, G. 2016. Clinical Validity of Tumor-Infiltrating Lymphocytes Analysis in Patients with Triple-Negative Breast Cancer. *Annals of Oncology*, 27: 249-256.

- Rahadi, P. N. K., Ruma, I. M. W., Wihandani, D. M., Supadmanaba, I. G. P., Adiputra, P. A. T. 2023. Hubungan *neutrophil lymphocyte ratio* dan *tumor infiltrating lymphocyte* dengan karakteristik klinikopatologi pasien *carcinoma* payudara di Rumah Sakit Umum Pusat Prof. Dr. I Goesti Ngoerah Gde Ngoerah Denpasar. *Medicina* 54(3): 179-185.
- Rakha, E. A., Reis-Filho, J. S., Baehner, F., Dabbs, D. J., Decker, T., Eusebi, V., Fox, S. B., Ichihara, S., Jacquemier, J., Lakhani, S. R., Palacios, J., Richardson, A. L., Schnitt, S. J., Schmitt, F. C., Tan, P. H., Tse, G. M., Badve, S., & Ellis, I. O. 2010. Breast cancer prognostic classification in the molecular era: the role of histological grade. *Breast cancer research : BCR*, 12(4): 207.
- Rey-Vargas, L., Bejarano-Rivera, L.M., López-Correa, P., Ballen-Lozano, D. & Serrano-Gómez, S.J. 2025. Differences in the distribution of HER2-positive breast tumors according to ethnicity and genetic variants in ERBB2: a special focus on Asian and Latina women. *Frontiers in Oncology*, 15.
- Salgado, R., Denkert, C., Demaria, S., Sirtaine, N., Klauschen, F., Pruneri, G., Wienert, S., van den Eynden, G., Baehner, F. L., Penault-Llorca, F., Perez, E. A., Thompson, E. A., Symmans, W. F., Richardson, A. L., Brock, J., Criscitiello, C., Bailey, H., Ignatiadis, M., Floris, G., ... Loi, S. (2015). The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: Recommendations by an International TILs Working Group 2014. In *Annals of Oncology* (Vol. 26, Issue 2, pp. 259–271). Oxford University Press. <https://doi.org/10.1093/annonc/mdu450>
- Schunke, M., Schulte, E., Schumacher, U. 2011. *Atlas Anatomi Manusia Prometheus: Anatomi dan Sistem Gerak Edisi 3*. Germany: Thieme.
- Schlam, I., Loi, S., Salgado, R., & Swain, S. M. 2025. Tumor-infiltrating lymphocytes in HER2-positive breast cancer: potential impact and challenges. *Elsevier B.V* 10(2).
- Setyawati, Y., Rahmawati, Y., Widodo, I., Ghazali, A., Purnomosari, D. 2018. The association between molecular subtypes of breast cancer with histological grade and lymph node metastases in Indonesian woman. *Asian Pacific Journal of Cancer Prevention*, 19(5): 1263-1268.
- Sherwood, L. 2016. *Human Physiology From Cells to Systems 9th Edition*. Canada: Cengage Learning.
- Shidqi, Z. N., Saraswati, L. D., Kusariana, N., Sutiningsih, D., Udijono, A. 2022. Faktor-Faktor Keterlambatan Diagnosis *Carcinoma* pada Pasien *Carcinoma* Payudara: Systematic Review. *Jurnal Epidemiologi Kesehatan Komunitas*, 7(2): 471-481.
- Siegel, R. L., Giaquinto, A. N., Jemal, A. 2024. Cancer statistics, 2024. *CA: A Cancer Journal for Clinicians*, 74(1): 12-49.

- Smolarz, B., Zadrozna Nowak, A., & Romanowicz, H. 2022. Breast Cancer—Epidemiology, Classification, Pathogenesis and Treatment (Review of Literature). *In Cancers*, 14 (10): 2569. MDPI.
- Spring, L.M. et al. 2020. Pathologic complete response after neoadjuvant chemotherapy and survival outcomes in breast cancer: a comprehensive meta-analysis. *JAMA Oncology*, 6(5), pp. 676–684.
- Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., Bray, F. 2021. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA Cancer Journal for Clinicians*, 71(3): 209-249.
- Tortorra, G. J., Derrickson, B. 2017. *Principles of Anatomy & Physiology 15th Edition*. United States of America, Wiley.
- Tsang, J. Y. S., Tse, G. M. 2020. Molecular Classification of Breast Cancer. *Advances in Anatomic Pathology*, 27(1): 27-35.
- Valenza, C., Salimbeni, B. T., Santoro, C., Trapani, D., Antonarelli, G., Curigliano, G. 2023. Tumor Infiltrating Lymphocytes across Breast Cancer Subtypes: Current Issues for Biomarker Assessment. *Cancers* 15, 767.
- Wang, M., Zhang, C., Song, Y., Wang, Z., Wang, Y., Luo, F., Xu, Y., Zhao, Y., Wu, Z., Xu, Y. 2017. Mechanism of Immune Evasion in Breast Cancer. *OncoTargets and Therapy*, 10: 1561-1573.
- WHO Classification of Tumours Editorial Board, Breast tumours. Lyon (France): International Agency for Research on Cancer, 2019. (WHO classification of tumours series, 5th ed; vol 2)
- Winasis, A., Djuwita, R. 2023. Obesitas dan *Carcinoma Payudara: Literature Review*. *Meida Publikasi Promosi Kesehatan Indonesia*: 6(8): 1501-1508.
- Winer, L., Ruth, K. J., Bleicher, R. J. Nagarathinam, R., McShane, M., Porpiglia, A. S., Pronovost, M. T., Aggon, A. Williams, A. D. 2025. Immunohistochemical status predicts pathologic complete response to neoadjuvant therapy in HER2-overexpressing breast cancers. *Annals of Surgical Oncology*, 32: 931-943.
- Wolff, A. C., Hammond, M. E. H., Allison, K. H., Harvey, B. E., Mangu, P. B., Bartlett, J. M. S., Bilous, M., Ellis, I. O., Fitzgibbons, P., Hanna, W., Jenkins, R. B., Press, M. F., Spears, P. A., Vance, G. H., Viale, G., McShane, L. M., & Dowsett, M. 2018. Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. *Journal of Clinical Oncology*, 36 (20): 2105-2122.

- Xiong, X., Zheng, L. W., Ding, Y. Chen, Y. F., Cai, Y. W., Wang, L. P., Huang, L., Liu, C. C. Shao, Z. M., Yu, K. D. 2025. Breast cancer: pathogenesis and treatments. *Signal Transduction and Targeted Therapy*, 10(49):
- Xu, T., He, B.S., Liu, X.X., Hu, X.X., Lin, K., Pan, Y.Q., Sun, H.L., Peng, H.X., Chen, X.X., Wang, S.K. 2017. The Predictive and Prognostic Role of Stromal Tumor-infiltrating Lymphocytes in HER2-positive Breast Cancer with Trastuzumab-based Treatment: a Meta-analysis and Systematic Review. *Journal of Cancer*, 8(18), 3838-3848.
- Zhong, H., Zhou, Z., Wang, H., Wang, R., Shen, K., Huang, R., Wang, Z. 2024. The Biological Roles and Clinical Applications of the PI3K/AKT Pathway in Targeted Therapy Resistance in HER2-Positive Breast Cancer: A Comprehensive Review. *International Journal of Molecular Sciences*, 25(24), 13376.

